BRIT J CANCER 润色咨询

BRITISH JOURNAL OF CANCER

出版年份：1947 年文章数：6101 投稿命中率： 开通期刊会员，数据随心看

出版周期：Semimonthly 自引率：2.4% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-05-03 ms8000000124135786

    大家投稿成功后一作会有收到邮件吗？

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2022-11-23 ms2000001925534900

    审稿速度:12.0 | 投稿命中率:5.0
    偏重的研究方向：肿瘤药理
    经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2022-11-29 ms4000001357719360 来自河南省

    这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2022-10-13 ms7000001682490134

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤
    经验分享：一审 小修
    Stage Start Date
    Revision Received 29th Aug 22
    Waiting for Revision 22nd Aug 22
    Decision made 22nd Aug 22
    Under consideration 20th Aug 22
    Under review 24th May 22
    Under consideration 15th May 22
    Author Approved Converted Files 15th May 22
    Under submission 15th May 22
    二审 初步接受
    Stage Start Date
    Revision Received 26th Sep 22
    Waiting for Revision 23rd Sep 22
    Decision made 23rd Sep 22
    Under consideration 22nd Sep 22
    Under review 3rd Sep 22
    Under consideration 29th Aug 22
    Author Approved Converted Files 29th Aug 22
    Under submission 29th Aug 22
    三审 正式接受
    Stage Start Date
    Decision made 29th Sep 22
    Under consideration 26th Sep 22
    Author Approved Converted Files 26th Sep 22
    Under submission 26th Sep 22
    审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2022-08-31 胸心外科大辣鸡

    偏重的研究方向：基础研究;肿瘤分子诊断
    经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2017-07-16 13805560183

    赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2022-03-22 122fdc42m84暂无昵称

    现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2022-05-25 淡霜凝眉

    审稿速度:6.0
    偏重的研究方向：肿瘤
    经验分享：一审
    Revision Received 20th Feb 22
    Waiting for Revision 25th Jan 22
    Decision made 25th Jan 22
    Under consideration 23rd Jan 22
    Under review 3rd Dec 21
    Under consideration 26th Nov 21
    Author Approved Converted Files 26th Nov 21
    Under submission 26th Nov 21
    二审
    Revision Received 13th Apr 22
    Waiting for Revision 13th Apr 22
    Decision made 13th Apr 22
    Under consideration 31st Mar 22
    Under review 25th Feb 22
    Under consideration 24th Feb 22
    Author Approved Converted Files 24th Feb 22
    Under submission 20th Feb 22
    作者排序修改
    Decision made 26th Apr 22
    Under consideration 14th Apr 22
    Author Approved Converted Files 14th Apr 22
    Under submission 13th Apr 22

    总体来说非常慢，外审2月，着急毕业不推荐

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2022-04-07 ms9000001367840543

    请问各位大神需要原始数据吗? 需要提前准备什么?

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102172, encodeId=288621021e22a, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤药理<br>经验分享：太太太太慢了，一审半年，补实验两个月，又等了四个月，最后拒稿！慎投！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3f785469539, createdName=ms2000001925534900, createdTime=Wed Nov 23 13:27:04 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103222, encodeId=82cf2103222d9, content=这本期刊信誉怎么样？业内认可度高吗？也属于老牌期刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34af8129929, createdName=ms4000001357719360, createdTime=Tue Nov 29 01:08:38 CST 2022, time=2022-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：一审 小修<br>Stage Start Date<br>Revision Received 29th Aug 22<br>Waiting for Revision 22nd Aug 22<br>Decision made 22nd Aug 22<br>Under consideration 20th Aug 22<br>Under review 24th May 22<br>Under consideration 15th May 22<br>Author Approved Converted Files 15th May 22<br>Under submission 15th May 22<br>二审 初步接受<br>Stage Start Date<br>Revision Received 26th Sep 22<br>Waiting for Revision 23rd Sep 22<br>Decision made 23rd Sep 22<br>Under consideration 22nd Sep 22<br>Under review 3rd Sep 22<br>Under consideration 29th Aug 22<br>Author Approved Converted Files 29th Aug 22<br>Under submission 29th Aug 22<br>三审 正式接受<br>Stage Start Date<br>Decision made 29th Sep 22<br>Under consideration 26th Sep 22<br>Author Approved Converted Files 26th Sep 22<br>Under submission 26th Sep 22<br>审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242219, encodeId=5a121242219b0, content=偏重的研究方向：基础研究;肿瘤分子诊断<br>经验分享：第九天under consideration，感觉跟别人的投稿进度比，效率有点慢哎，送不送外审要好久哦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Wed Aug 31 09:48:26 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544294, encodeId=d79e544294ed, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=429, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205029, encodeId=f89e120502967, content=现在要求链接所有通讯作者的ORCID号，但是投稿系统只有一个能标通讯作者有链接，另一个咋办啊？还有其他可以添加ORCID号的地方吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/07/6b605841361be17ba96637bccdbdccb4.jpg, createdBy=eaa62374501, createdName=122fdc42m84暂无昵称, createdTime=Tue Mar 22 20:59:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222433, encodeId=3b9a1222433c8, content=审稿速度:6.0<br>偏重的研究方向：肿瘤<br>经验分享：一审<br>Revision Received 20th Feb 22<br>Waiting for Revision 25th Jan 22<br>Decision made 25th Jan 22<br>Under consideration 23rd Jan 22<br>Under review 3rd Dec 21<br>Under consideration 26th Nov 21<br>Author Approved Converted Files 26th Nov 21<br>Under submission 26th Nov 21<br>二审<br>Revision Received 13th Apr 22<br>Waiting for Revision 13th Apr 22<br>Decision made 13th Apr 22<br>Under consideration 31st Mar 22<br>Under review 25th Feb 22<br>Under consideration 24th Feb 22<br>Author Approved Converted Files 24th Feb 22<br>Under submission 20th Feb 22<br>作者排序修改<br>Decision made 26th Apr 22<br>Under consideration 14th Apr 22<br>Author Approved Converted Files 14th Apr 22<br>Under submission 13th Apr 22<br><br>总体来说非常慢，外审2月，着急毕业不推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=20851720534, createdName=淡霜凝眉, createdTime=Wed May 25 21:34:50 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209414, encodeId=8599120941464, content=请问各位大神需要原始数据吗? 需要提前准备什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1495413486, createdName=ms9000001367840543, createdTime=Thu Apr 07 23:27:33 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008695, encodeId=17f31008695d0, content=under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Tue Aug 17 14:15:09 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-08-17 H·D·E

    under review两个月，结果只回来一个审稿人的意见，就把我给拒了.这也太离谱了

    0

共188条页码: 2/19页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分